First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

被引：199

作者：

Herrmann, Ken ^{[1
,2
,3
]}

Schottelius, Margret ^{[4
]}

Lapa, Constantin ^{[1
]}

Osl, Theresa ^{[4
]}

Poschenrieder, Andreas ^{[4
]}

Haenscheid, Heribert ^{[1
]}

Lueckerath, Katharina ^{[1
]}

Schreder, Martin ^{[5
]}

Bluemel, Christina ^{[1
]}

Knott, Markus ^{[5
]}

Keller, Ulrich ^{[6
,7
,8
]}

Schirbel, Andreas ^{[1
]}

Samnick, Samuel ^{[1
]}

Lassmann, Michael ^{[1
]}

Kropf, Saskia ^{[9
]}

Buck, Andreas K. ^{[1
]}

Einsele, Hermann ^{[5
]}

Wester, Hans-Juergen ^{[4
]}

Knop, Stefan ^{[5
]}

机构：

[1] Univ Hosp Wurzburg, Dept Nucl Med, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[4] Tech Univ Munich, Pharmaceut Radiochem, D-80290 Munich, Germany

[5] Univ Klinikum Wurzburg, Div Hematol & Med Oncol, Dept Internal Med 2, Wurzburg, Germany

[6] Tech Univ Munich, Dept Med Hematol Oncol 3, D-80290 Munich, Germany

[7] German Canc Consortium DKTK, Heidelberg, Germany

[8] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany

[9] Scintomics GmbH, Furstenfeldbruck, Germany

来源：

JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷 / 02期

关键词：

multiple myeloma; CXCR4; endoradiotherapy; pentixather; CXCR4; EXPRESSION; THERAPY; AXIS; PET;

D O I：

10.2967/jnumed.115.167361

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand (Ga-68-pentixafor) for diagnostic receptor targeting, Lu-177- and Y-60-pentixather were recently developed as endoradiotherapeutic vectors. Here, we summarize the first-in-human experience in 3 heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma undergoing CXCR4-directed endoradiotherapy. Methods: CXCR4 target expression was demonstrated by baseline Ga-68-pentixafor PET. Each treatment was approved by the clinical ethics committee. Pretherapeutic Lu-177-pentixather dosimetry was performed before Lu-177-pentixather or Y-60-pentixather treatment. Subsequently, patients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue. Results: A remarkable therapeutic effect was visualized in 2 patients, who showed a significant reduction in F-18-FDG uptake. Conclusion: CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stern cell transplantation, especially for patients with advanced multiple myeloma.

引用

页码：248 / 251

页数：4

共 20 条

[1] The impact of intra-clonal heterogeneity on the treatment of multiple myeloma [J].

Brioli, Annamaria ;

Melchor, Lorenzo ;

Cavo, Michele ;

Morgan, Gareth J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) :441-454

[2] CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers [J].

Burger, J. A. ;

Peled, A. .

LEUKEMIA, 2009, 23 (01) :43-52

[3]

Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109

[4]

de Jong M, 2005, J NUCL MED, V46, p13S

[5]

de la Puente Pilar, 2014, Leuk Res Treatment, V2014, P976567, DOI 10.1155/2014/976567

[6] PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand [J].

Demmer, Oliver ;

Gourni, Eleni ;

Schumacher, Udo ;

Kessler, Horst ;

Wester, Hans-Juergen .

CHEMMEDCHEM, 2011, 6 (10) :1789-1791

[7] A review on CXCR4/CXCL12 axis in oncology: No place to hide [J].

Domanska, Urszula M. ;

Kruizinga, Roeliene C. ;

Nagengast, Wouter B. ;

Timmer-Bosscha, Hetty ;

Huls, Gerwin ;

de Vries, Elisabeth G. E. ;

Walenkamp, Annemiek M. E. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) :219-230

[8] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[9] PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent [J].

Gourni, Eleni ;

Demmer, Oliver ;

Schottelius, Margret ;

D'Alessandria, Calogero ;

Schulz, Stefan ;

Dijkgraaf, Ingrid ;

Schumacher, Udo ;

Schwaiger, Markus ;

Kessler, Horst ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (11) :1803-1810

[10] Minimal Residual Disease in Multiple Myeloma [J].

Munshi, Nikhil C. ;

Anderson, Kenneth C. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2523-2526

← 1 2 →